DarioHealth CEO granted 297,000 restricted shares

Q: When does Raphael Erez's DRIO restricted share award vest?

It is scheduled to vest in eight equal quarterly installments on the last day of each successive calendar quarter after the September 24, 2026 grant date, over a two-year period.

Q: How many DarioHealth common shares followed Raphael Erez's Series B-2 conversion?

His 30 Series B-2 Preferred Stock shares automatically converted into 11,574 common shares on August 12, 2024. After the subsequent reverse stock split, the conversion shares were reported as 579 common shares. Erez also received common shares under the Series B Preferred Stock dividend provisions.

The restricted share award is scheduled to vest in eight equal quarterly installments on the last day of successive quarters over two years.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

DarioHealth Corp. Chief Executive Officer Raphael Erez was granted a direct restricted share award of 297,000 common shares on September 24, 2026; no Rule 10b5-1 plan is reported. Separately, 30 Series B-2 Preferred Stock shares automatically converted on August 12, 2024, into 11,574 common shares, with the conversion shares reported as 579 shares following a reverse stock split. Erez beneficially owned 157,432 common shares immediately following the August 12, 2024 conversion.

Insider Trade Summary

30 shares exercised/converted

Exercise 4 txns

Insider Raphael Erez

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock ^F3	297,000	$0.00	$0.00
Conversion	Series B-2 Preferred Stock	30	$1,000.00	$30K
Conversion	Common Stock ^{F1, F2}	579	$19.10	$11K
holding	Common Stock	--	--	--

Holdings After Transaction: Series B-2 Preferred Stock — 0 contracts (Direct); Common Stock — 454,432 shares (Direct); Common Stock — 1,894 shares (Indirect, By Dicilyon Consulting and Investment Ltd.)

Footnotes (3)

F1. Pursuant to its terms, the Series B Preferred Stock automatically converted into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date.
F2. The Reporting Person's 30 shares of Series B-2 Preferred Stock automatically converted into 11,574 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 579 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 157,432 shares of Common Stock immediately following the conversion.
F3. The restricted share award shall vest in eight equal quarterly installments on the last day of each successive calendar quarter after the grant date over a two-year period.

Key Figures

Restricted share award: 297,000 common shares Vesting installments: 8 equal quarterly installments Series B-2 Preferred Stock conversion: 30 shares +3 more

6 metrics

Restricted share award 297,000 common shares Granted to Raphael Erez on September 24, 2026

Vesting installments 8 equal quarterly installments On the last day of successive calendar quarters after the grant date

Series B-2 Preferred Stock conversion 30 shares Automatically converted on August 12, 2024

Common shares from conversion 11,574 shares Automatically converted on August 12, 2024, before the subsequent reverse stock split

Common shares reported after reverse stock split 579 shares Conversion shares following the subsequent reverse stock split

Common shares beneficially owned 157,432 shares Immediately following the August 12, 2024 conversion, after giving effect to the reverse stock split and dividend shares

Key Terms

restricted share award, beneficial ownership limitations, non-waivable 19.99% ownership blocker, reverse stock split

4 terms

beneficial ownership limitations regulatory

"subject to certain beneficial ownership limitations"

Beneficial ownership limitations are rules or contractual caps that restrict how much of a company’s stock an individual or entity can be treated as owning or controlling for legal, regulatory or corporate-governance purposes. They matter to investors because such limits affect voting power, reporting obligations, takeover risk and the ability to increase a stake — like an elevator weight limit or a lane divider that prevents any one car from taking over the whole road.

non-waivable 19.99% ownership blocker regulatory

"including a non-waivable 19.99% ownership blocker"

reverse stock split financial

"Following the Issuer's subsequent reverse stock split"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did DarioHealth CEO Raphael Erez receive in his DRIO award?

Raphael Erez was granted a direct restricted share award of 297,000 common shares on September 24, 2026. No Rule 10b5-1 plan is reported.

How many DarioHealth common shares followed Raphael Erez's Series B-2 conversion?

His 30 Series B-2 Preferred Stock shares automatically converted into 11,574 common shares on August 12, 2024. After the subsequent reverse stock split, the conversion shares were reported as 579 common shares. Erez also received common shares under the Series B Preferred Stock dividend provisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/28/2026 - 04:06 PM Accepted by SEC EDGAR 09/28/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raphael Erez

(Last)

(First)

(Middle)

322 W 57TH STREET, #33B

(Street)

NEW YORK

10019

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DarioHealth Corp. [ DRIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2024

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/12/2024⁽¹⁾		C		579⁽²⁾	A	$19.1⁽²⁾	157,432⁽²⁾	D
Common Stock	09/24/2026⁽³⁾		A		297,000	A	$0	454,432	D
Common Stock								1,894	I	By Dicilyon Consulting and Investment Ltd.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series B-2 Preferred Stock	$1,000	08/12/2024		C			30	05/04/2023	08/04/2024	Common Stock	579	$1,000	0	D

Explanation of Responses:

1. Pursuant to its terms, the Series B Preferred Stock automatically converted into shares of common stock, subject to certain beneficial ownership limitations, including a non-waivable 19.99% ownership blocker, on the 15-month anniversary of the issuance date.

2. The Reporting Person's 30 shares of Series B-2 Preferred Stock automatically converted into 11,574 shares of Common Stock on August 12, 2024. Following the Issuer's subsequent reverse stock split, the conversion shares are reported as 579 shares of Common Stock. The Reporting Person also received shares of Common Stock pursuant to the dividend provisions applicable to the Series B Preferred Stock. After giving effect to the reverse stock split and such dividend shares, the Reporting Person beneficially owned 157,432 shares of Common Stock immediately following the conversion.

3. The restricted share award shall vest in eight equal quarterly installments on the last day of each successive calendar quarter after the grant date over a two-year period.

	/s/ Erez Raphael	09/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR